NCT00599092

Brief Summary

The purpose of this study is to observe predictors of pituitary tumor recurrence and markers of persistent disease activity in patients harboring pituitary mass lesions of all types.

Trial Health

77
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
1,250

participants targeted

Target at P75+ for all trials

Timeline
299mo left

Started Jan 1997

Longer than P75 for all trials

Geographic Reach
1 country

1 active site

Status
recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress54%
Jan 1997Dec 2050

Study Start

First participant enrolled

January 1, 1997

Completed
11 years until next milestone

First Submitted

Initial submission to the registry

January 11, 2008

Completed
12 days until next milestone

First Posted

Study publicly available on registry

January 23, 2008

Completed
42.9 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 1, 2050

Expected
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

December 1, 2050

Last Updated

March 23, 2026

Status Verified

March 1, 2026

Enrollment Period

54 years

First QC Date

January 11, 2008

Last Update Submit

March 19, 2026

Conditions

Pituitary Tumor

Keywords

pituitary tumorrecurrence

Outcome Measures

Primary Outcomes (1)

  • Overall Survival (Longevity)

    Overall survival will be measured from study enrollment (or diagnosis, as applicable) to death from any cause. Survival status will be determined through electronic medical records and, if necessary, supplemented by publicly available death records (e.g., National Death Index).

    20 years

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

tertiary referral center

You may qualify if:

  • patients with confirmed pituitary disease

You may not qualify if:

  • patients who do not have confirmed pituitary disease

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Cedars-Sinai Medical Center, Pituitary Center

Los Angeles, California, 90048, United States

RECRUITING

Biospecimen

Retention: SAMPLES WITH DNA

whole blood

MeSH Terms

Conditions

Pituitary NeoplasmsRecurrence

Condition Hierarchy (Ancestors)

Endocrine Gland NeoplasmsNeoplasms by SiteNeoplasmsHypothalamic NeoplasmsSupratentorial NeoplasmsBrain NeoplasmsCentral Nervous System NeoplasmsNervous System NeoplasmsBrain DiseasesCentral Nervous System DiseasesNervous System DiseasesHypothalamic DiseasesPituitary DiseasesEndocrine System DiseasesDisease AttributesPathologic ProcessesPathological Conditions, Signs and Symptoms

Study Officials

  • Shlomo Melmed, MD

    Cedars-Sinai Medical Center, Pituitary Center

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
observational
Observational Model
OTHER
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Professor of Medicine

Study Record Dates

First Submitted

January 11, 2008

First Posted

January 23, 2008

Study Start

January 1, 1997

Primary Completion (Estimated)

December 1, 2050

Study Completion (Estimated)

December 1, 2050

Last Updated

March 23, 2026

Record last verified: 2026-03

Locations

US(1)